While this is often a concern in immunotherapy60, the AbTCR approach is independent of other mechanisms of resistance (such as BRAF mutations in HCC, which can lead to resistance against tyrosine kinase inhibitors61) and could thus be beneficial when used supplemental to or along with other therapies. This evidence concerns the gene BRAF and hepatocellular carcinoma.